1[1]Martin GB,Rivers EP,Paradis NA,et al. Emergency department cardiopulmonary bypass in the treament of human cardiac arrest [ J ].Chest, 1998, 13: 743-751
4Gourlay T.Biomaterial development for cardiopulmonary bypass.Perfusion,2001,16:381-390.
5American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med,1992,20:864-874.
6Hornick P,George A.Blood contact activation:pathophysiological effects and therapeutic approaches.Perfusion,1996,11:3-19.
8Fransen E,Maessen J,Dentener M,et al.Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery.Chest,1999,116:1233-1239.
9Hardy JF,Martineau R,Couturier A,et al.Influence of haemoglobin concentration after extracorporeal circulation on mortality and morbidity in patients undergoing cardiac surgery.Br J Anaesth,1998,81:38-45.
10Jansen PG,Te Velthuis H,Oudemans-Van Straaten HM,et al.Perfusion-related factors of endotoxin release during cardiopulmonary bypass.Eur J Cardiothorac Surg,1994,8:125-129.
